Company news
Fortress Biotech, Inc. news in 2023
Fortress Biotech, Inc.'s news releases, calls and decks from 2023, newest first.
Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 28, 2023
Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.
December 5, 2023
Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
November 13, 2023
Fortress Biotech Announces Closing of $10.0 Million Public Offering
November 13, 2023
Fortress Biotech Announces Pricing of $10.0 Million Public Offering
November 9, 2023
Fortress Biotech Announces Launch of Proposed Public Offering
November 8, 2023
Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1
October 15, 2023
Fortress Biotech Announces Reverse Stock Split
October 8, 2023
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
August 13, 2023
Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program
June 14, 2023
Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
May 14, 2023
Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H
April 23, 2023
Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights
March 29, 2023
Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
February 7, 2023